AnaptysBio (NASDAQ:ANAB) Insider Sells $100,820.85 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 2,235 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $100,820.85. Following the completion of the transaction, the insider owned 37,213 shares in the company, valued at $1,678,678.43. This represents a 5.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

AnaptysBio Trading Down 3.1%

Shares of AnaptysBio stock traded down $1.41 on Thursday, hitting $43.80. 1,747,008 shares of the company traded hands, compared to its average volume of 768,760. The company has a market cap of $1.21 billion, a PE ratio of -15.53 and a beta of 0.32. The stock’s 50 day moving average price is $42.31 and its 200-day moving average price is $31.22. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $52.47.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has initiated a share repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently made changes to their positions in ANAB. Larson Financial Group LLC lifted its holdings in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the last quarter. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares during the last quarter. Finally, Covestor Ltd grew its stake in shares of AnaptysBio by 131,540.0% during the third quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 6,577 shares during the last quarter.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of research reports. UBS Group assumed coverage on shares of AnaptysBio in a research note on Wednesday. They issued a “buy” rating and a $70.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. Truist Financial increased their target price on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Barclays decreased their price objective on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and an average target price of $60.40.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.